<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04623801</url>
  </required_header>
  <id_info>
    <org_study_id>19-438</org_study_id>
    <nct_id>NCT04623801</nct_id>
  </id_info>
  <brief_title>Laser Ablation of Papillary Thyroid Microcarcinoma</brief_title>
  <official_title>Pilot Study to Evaluate the Safety and Efficacy of Percutaneous Laser Ablation of Thyroid Papillary Microcarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore whether percutaneous laser ablation (PLA) is a safe&#xD;
      and effective alternative to removing papillary thyroid microcarcinoma (PTMC) with surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2020</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with complete thermal ablation</measure>
    <time_frame>6 months</time_frame>
    <description>Complete thermal ablation of the targeted PTMC (T1aN0M0) as determined by histological examination of thyroid tissue obtained by either thyroid lobectomy or total thyroidectomy 6 months after PLA.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Papillary Thyroid Microcarcinoma</condition>
  <condition>Thyroid</condition>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Participants with papillary microcarcinoma (PTMC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with papillary microcarcinoma (PTMC) who have elected to proceed with thyroidectomy rather than an observational management approach will be considered as potential candidates for this trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous Laser Ablation (PLA)</intervention_name>
    <description>Percutaneous Laser Ablation / PLA will be carried out in a single session by advancing one 21-gauge spinal needle into the target lesions under real time US guidance.</description>
    <arm_group_label>Participants with papillary microcarcinoma (PTMC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Cytologically confirmed papillary thyroid microcarcinoma&#xD;
&#xD;
          -  Maximum diameter ≤ 13 mm&#xD;
&#xD;
          -  Declined active surveillance&#xD;
&#xD;
          -  The thyroid lesion must be primarily solid with ≤ 25% cystic compent&#xD;
&#xD;
          -  No US evidence of extrathyroidal extension through the thyroid capsule&#xD;
&#xD;
          -  No imaging evidence of lymph node metastasis&#xD;
&#xD;
          -  Preserved contralateral vocal cord function prior to PLA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Thyroid cancer that is non papillary thyroid cancer (PTC)&#xD;
&#xD;
          -  Thyroid lesion with &gt; 25% cystic component&#xD;
&#xD;
          -  Lesion with US evidence of extrathyroidal extension through the thyroid capsule&#xD;
&#xD;
          -  Clinical or ultrasonographic evidence of lymph node metastasis&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. Michael Tuttle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>R. Michael Tuttle, MD</last_name>
    <phone>646-608-3910</phone>
    <email>tuttler@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephen Solomon, MD</last_name>
    <phone>212-639-5012</phone>
    <email>solomons@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. Michael Tuttle, MD</last_name>
      <phone>646-608-3910</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTMC</keyword>
  <keyword>Papillary Thyroid Microcarcinoma</keyword>
  <keyword>Thyroid Cancer</keyword>
  <keyword>Percutaneous Laser Ablation</keyword>
  <keyword>PLA</keyword>
  <keyword>19-438</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Papillary</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

